Search Result

Pathways Recommended:	Stem Cell/Wnt Cell Cycle/DNA Damage

Results for "

A2780 ovarian cancer cells

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (1) Angiotensin-converting Enzyme (ACE) (1) Apoptosis (16) ATM/ATR (2) Aurora Kinase (2) Autophagy (1) Bacterial (1) Bcl-2 Family (1) Biochemical Assay Reagents (2) c-Myc (1) Caspase (1) CDK (4) Checkpoint Kinase (Chk) (2) Cytochrome P450 (1) DNA/RNA Synthesis (2) Drug Derivative (2) Drug Intermediate (2) Drug Metabolite (1) E1/E2/E3 Enzyme (1) Early 2 Factor (E2F) (1) Endogenous Metabolite (1) Epigenetic Reader Domain (1) ERK (1) FAK (1) Fluorescent Dye (1) HDAC (5) Histone Acetyltransferase (1) HIV (1) MDM-2/p53 (2) Microtubule/Tubulin (2) Mitochondrial Metabolism (1) MMP (1) Mps1 (1) mTOR (2) Parasite (2) PARP (1) PI3K (3) Potassium Channel (2) Reference Standards (2) Src (1) TAM Receptor (1) Thymidylate Synthase (1) Topoisomerase (1) VEGFR (1)
By Research Areas:	Cancer (36) Cardiovascular Disease (3) Endocrinology (1) Infection (5)

By Targets:

Akt (1)

Angiotensin-converting Enzyme (ACE) (1)

Apoptosis (16)

ATM/ATR (2)

Aurora Kinase (2)

Autophagy (1)

Bacterial (1)

Bcl-2 Family (1)

Biochemical Assay Reagents (2)

c-Myc (1)

Caspase (1)

CDK (4)

Checkpoint Kinase (Chk) (2)

Cytochrome P450 (1)

DNA/RNA Synthesis (2)

Drug Derivative (2)

Drug Intermediate (2)

Drug Metabolite (1)

E1/E2/E3 Enzyme (1)

Early 2 Factor (E2F) (1)

Endogenous Metabolite (1)

Epigenetic Reader Domain (1)

ERK (1)

FAK (1)

Fluorescent Dye (1)

HDAC (5)

Histone Acetyltransferase (1)

HIV (1)

MDM-2/p53 (2)

Microtubule/Tubulin (2)

Mitochondrial Metabolism (1)

MMP (1)

Mps1 (1)

mTOR (2)

Parasite (2)

PARP (1)

PI3K (3)

Potassium Channel (2)

Reference Standards (2)

Src (1)

TAM Receptor (1)

Thymidylate Synthase (1)

Topoisomerase (1)

VEGFR (1)

By Research Areas:

Cancer (36)

Cardiovascular Disease (3)

Endocrinology (1)

Infection (5)

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Natural
Products

Targets Recommended: Nuclear Factor of activated T Cells (NFAT) BCRP TREM receptor

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-153278

Q901 CDK7-IN-21	CDK DNA/RNA Synthesis c-Myc Early 2 Factor (E2F) Topoisomerase	Cancer
Q901 (CDK7-IN-21) is a selective and potent CDK7 inhibitor with an IC₅₀ of 10 nM. Q901 disrupts MYC and E2FTOP1-DPCs and sensitizes tumor to TOP1 inhibitors by suppressing RNAPII transition from initiation to elongation. Q901 can inhibit tumor growth and significantly enhances tumor growth inhibition combined with TOP1 inhibitors. Q901 can be used for the research of cancer, such as colon cancer and lung cancer .

HY-12496

NS-1619 4 Publications Verification	Potassium Channel Apoptosis	Cardiovascular Disease Cancer
NS-1619 is an opener of large conductance Ca ²⁺-activated K ⁺ (BK) channel. NS-1619 is a highly effective relaxant with an EC₅₀ of about 10 – 30 μM in several smooth muscles of blood vessels and other tissues . NS1619 inhibits proliferation and induces apoptosis in A2780 ovarian cancer cells .

HY-N0245

Theaflavin-3-gallate	Apoptosis MDM-2/p53 ATM/ATR Checkpoint Kinase (Chk)	Cancer
Theaflavin-3-gallate, a black tea theaflavin monomer, is regarded as the biologically important active component of black tea and provides health benefits. Theaflavin-3-gallate acts as prooxidants and induces oxidative stress in the carcinoma cells. Theaflavin-3-gallate reacts directly with reduced glutathione (GSH) in a time- and concentration-dependent manner. Theaflavin-3-gallate induces apoptosis and G1 cell cycle arrest in ovarian cancer A2780/CP70 cells through p53-dependent pathways. Theaflavin-3-gallate induces DNA damage through ATM/Chk/p53 pathway .

HY-15275

BMS-265246 2 Publications Verification	CDK Angiotensin-converting Enzyme (ACE)	Infection Cardiovascular Disease Cancer
BMS-265246 is a potent and selective cyclin-dependent kinase CDK1 and CDK2 inhibitor, with IC₅₀ values of 6 and 9 nM, respectively. BMS-265246 inhibits CHI3L1 (chitinase 3-like-1) stimulation of ACE2 (angiotensin converting enzyme 2) and SPP (viral spike protein priming proteases). BMS-265246 can be used for ovarian cancer and COVID-19 research .

HY-12003

SNS-314 mesylate 3 Publications Verification	Aurora Kinase	Cancer
SNS-314 mesylate is a potent and selective aurora kinase inhibitor with IC₅₀s of 9, 31, and 6 nM for aurora A, B and C, respectively .

HY-B1022

Dimesna 1 Publications Verification BNP-7787	Drug Derivative	Endocrinology Cancer
Dimesna (BNP-7787), the disulfide form of Mesna (HY-13679), is a platinum-related toxicity protective agent. Dimesna converts to Mesna, which in turn inactivates toxic platinum substances. Dimesna does not interfere with the antitumor activity of platinum compounds. Dimesna does not affect the antiproliferative effects of Cisplatin (HY-17394) or Carboplatin (HY-17393). Dimesna counteracts Cisplatin-induced nephrotoxicity. Dimesna exerts selective protective effects on the kidneys. Dimesna can be used in studies related to ovarian cancer and Cisplatin-induced nephrotoxicity .

HY-D2452

Cy3-Cisplatin 1 Publications Verification	Fluorescent Dye	Others
Cy3-Cisplatin is a Cyanine 3 fluorescent dye CY3 (HY-D0822) labled Cisplatin (HY-17394). Cy3-Cisplatin can be used for drug delivery, fluorescent labeling, cell imaging and tracking .

HY-W096169D

Platinum	Biochemical Assay Reagents Drug Intermediate	Cancer
Platinum is a metallic element, and its complexes act as orally active anticancer agents. Platinum-based complexes used for tumors include Cisplatin (HY-17394), Carboplatin (HY-17393), and Oxaliplatin (HY-17371) .

HY-123888

Viomellein	E1/E2/E3 Enzyme Bacterial	Cancer
Viomellein is a SUMOylation inhibitor with antibacterial and anticancer activities. Viomellein inhibits biofilm formation of strains produced from the fungus Aspergillus ochraceus from the Mediterranean sponge Agelas oroides. Viomellein exhibits cytotoxicity against A2780 human ovarian cancer cells with an IC₅₀ value of 5.0 μM. Viomellein also inhibits SUMOylation of RanGAP1 (GTPase activating protein) with an IC₅₀ of 10.2 μM .

HY-N16573

19-epi-Voacristine	Others	Cancer
19-epi-Voacristine is an indole alkaloid. 19-epi-Voacristine exhibits cytotoxic activity against the A2780 ovarian cancer cell line .

HY-N6926

1,3,5-Tricaffeoylquinic acid	HIV Apoptosis Caspase VEGFR ERK PI3K Akt mTOR PARP	Infection Cancer
1,3,5-Tricaffeoylquinic acid acts as an angiogenesis inhibitor and apoptosis inducer, and exhibits anti-HIV activity. 1,3,5-Tricaffeoylquinic acid inhibits the phosphorylation of VEGFR2, ERK, PI3K, Akt and mTOR in the angiogenesis signaling pathway. 1,3,5-Tricaffeoylquinic acid regulates apoptosis-related proteins, upregulates the levels of activated caspase-8, Bax, activated PARP and caspase-3/9, while downregulates the level of Bcl-2. 1,3,5-Tricaffeoylquinic acid inhibits tube formation and shows cytotoxicity against ovarian cancer cells. 1,3,5-Tricaffeoylquinic acid can be used in studies related to ovarian cancer .

HY-124348

DM-PIT-1 3,5-Dimethyl PIT-1	PI3K	Cancer
DM-PIT-1 is a PIP3/PH (phosphatidylinositol-3,4,5-triphosphate/Pleckstrin) interaction inhibitor. DM-PIT-1 decreases he expression of P-Akt, P-GSK-3-β, P-p70S6K, P-S6, P-4E-BP1. DM-PIT-1 induces apoptosis and shows anticancer activity. DM-PIT-1 has the potential for the research of ovarian cancer .

HY-108344

SNS-314	Aurora Kinase	Cancer
SNS-314 is a potent and selective aurora kinase inhibitor with IC₅₀s of 9, 31, and 6 nM for aurora A, B and C, respectively .

HY-P2228

Chlamydocin (purity≥70%)	HDAC Apoptosis	Cancer
Chlamydocin (purity≥70%), a fungal metabolite, is a highly potent HDAC inhibitor, with an IC₅₀ of 1.3 nM. Chlamydocin (purity≥70%) exhibits potent antiproliferative and anticancer activities. Chlamydocin (purity≥70%) induces apoptosis by activating caspase-3 .

HY-10226

JNJ-16241199 R306465	Apoptosis HDAC	Cancer
JNJ-16241199 (R306465) is an orally active, selectivehydroxamate-based histone deacetylase (HDAC) inhibitor, with theIC₅₀of 3.3 nM and 23 nM for HDAC1and HDAC8, respectively.JNJ-16241199induces histone 3 acetylation and strongly increases the expression of p21 ^waf1, ^cip1 in A2780 ovarian carcinoma cells.JNJ-16241199 inducescell apoptosisand shows anticancer activityin a broad spectrum of human malignancies. JNJ-16241199 can be used for cancer study .

HY-175857

HDAC-IN-92	HDAC Apoptosis	Cancer
HDAC-IN-92 is a pan-HDAC inhibitor with an IC₅₀ of 12.58 µM in A2780 cells. HDAC-IN-92 demonstrates broad-spectrum, notable cytotoxic activity against a range of human cancer cell lines, including ovarian, liver, and breast carcinomas. HDAC-IN-92 causes apoptosis and demonstrates a notable decrease in tumor cell colony formation. HDAC-IN-92 inhibits the formation of blood vessels in the chick chorioallantoic membrane (CAM). HDAC-IN-92 exhibits anti-tumor effect in a 4T1 tumor-bearing mouse model. HDAC-IN-92 can be used for research targeting solid tumor .

HY-169477

PAMAM dendrimer G0.5 carboxylate sodium (8.78% w/w in water)	Biochemical Assay Reagents	Cancer
PAMAM Dendrimer G0.5 Carboxylate sodium is a polyamidoamine (PAMAM) dendrimer with carboxylate termini. PAMAM Dendrimer G0.5 Carboxylate sodium conjugated with DACHPt is cytotoxic to A2780 ovarian cancer cells, MCF-7 breast cancer cells, Caco-2 colon cancer cells and BJ fibroblasts with IC₅₀ values of 0.03, 1.6, 0.18 and 3 µM, respectively .

HY-123034

CDKI-83	CDK Bcl-2 Family Apoptosis	Cancer
CDKI-83 is a potent CDK9 and CDK1 inhibitor with K_i values of 21 nM and 72 nM for CDK9/T1 and CDK1/B, respectively. CDKI-83 demonstrates effective anti-proliferative activity in human tumour cell lines with a GI₅₀<1 μM. CDKI-83 effectively induces apoptosis in A2780 human ovarian cancer cells. CDKI-83 reduces phosphorylation at Ser-2 of RNA polymerase II (RNAPII) by inhibiting cellular CDK9 activity, and down-regulates Mcl-1 and Bcl-2. CDKI-83 has the potential for anti-cancer research .

HY-174160

MerTK-IN-2	TAM Receptor Apoptosis	Cancer
MerTK-IN-2 (compound 15f) is an orally active MerTK inhibitor with an IC₅₀ of 37.5 nM. MerTK-IN-2 can induce apoptosis. MerTK-IN-2 has antitumor activity with IC₅₀ values of 1.79, 18.32, and 2.18 μM for human ovarian cancer cells A2780, breast cancer cells MDA-MB-231, and colon cancer cells HCT116, respectively .

HY-N10268

3-Hydroxyterphenyllin NSC 299113	Apoptosis	Cancer
3-Hydroxyterphenyllin is a metabolite of Aspergillus candidus.3-Hydroxyterphenyllin suppresses proliferation and causes cytotoxicity against A2780/CP70 and OVCAR-3 cells. 3-Hydroxyterphenyllin induces S phase arrest and apoptosis. 3-Hydroxyterphenyllin has the potential for the research of ovarian cancer .

HY-12496R

NS-1619 (Standard)	Potassium Channel Apoptosis	Cardiovascular Disease Cancer
NS-1619 (Standard) is the analytical standard of NS-1619. This product is intended for research and analytical applications. NS-1619 is an opener of large conductance Ca2+-activated K+ (BK) channel. NS-1619 is a highly effective relaxant with an EC50 of about 10-30 μM in several smooth muscles of blood vessels and other tissues . NS1619 inhibits proliferation and induces apoptosis in A2780 ovarian cancer cells .

HY-143339

CBP/p300-IN-15	Epigenetic Reader Domain Histone Acetyltransferase	Cancer
CBP/p300-IN-15 (compound 13a) is a potent p300/CBP inhibitor, with IC₅₀ values of 2.50 and 28.0 nM, respectively. CBP/p300-IN-15 shows good activity against OVCAR-3 and A2780 cell line, with EC₅₀ values of 0.865 and 2.71 μM, respectively. CBP/p300-IN-15 can be used for ovarian cancer research .

HY-N0245R

Theaflavin-3-gallate (Standard)	Reference Standards Apoptosis MDM-2/p53 ATM/ATR Checkpoint Kinase (Chk)	Cancer
Theaflavin-3-gallate (Standard) is the analytical standard of Theaflavin-3-gallate. This product is intended for research and analytical applications. Theaflavin-3-gallate, a black tea theaflavin monomer, is regarded as the biologically important active component of black tea and provides health benefits. Theaflavin-3-gallate acts as prooxidants and induces oxidative stress in the carcinoma cells. Theaflavin-3-gallate reacts directly with reduced glutathione (GSH) in a time- and concentration-dependent manner. Theaflavin-3-gallate induces apoptosis and G1 cell cycle arrest in ovarian cancer A2780/CP70 cells through p53-dependent pathways. Theaflavin-3-gallate induces DNA damage through ATM/Chk/p53 pathway .

HY-182734

BMS-357075	CDK	Cancer
BMS-357075 is a pan-CDK inhibitor with CDK1 IC₅₀ 18 nM, CDK2 IC₅₀ 3 nM, CDK4 IC₅₀ 26 nM. BMS-357075 induces cytotoxicity in human ovarian cancer A2780 cells. BMS-357075 exhibits anticancer activity in mice against P388 murine leukemia. BMS-357075 can be used for the research of leukemia .

HY-N3446

IVHD-valtrate	Apoptosis	Cancer
IVHD-valtrate, an active Valeriana jatamansi derivative, is against human ovarian cancer cells in vitro and in vivo. IVHD-valtrate induces cancer cells apoptosis and arrests the ovarian cancer cells in the G2/M phase. IVHD-valtrate has the potential to be a novel chemotherapeutic agent for the human ovarian cancer research .

HY-161824

Antiproliferative agent-52	Drug Intermediate Microtubule/Tubulin	Cancer
Antiproliferative agent-52 is a tubulin inhibitor with a porcine tubulin K_D of 29.65 μM. Antiproliferative agent-52 binds to the colchicine-binding site at the α-tubulin and β-tubulin interface and inhibits tubulin polymerization. Antiproliferative agent-52 exhibits antiproliferative activity against tumor cells. Antiproliferative agent-52 serves as a lead compound for development of thienopyrimidine and heterocyclic fused pyrimidines with antiproliferative activity. Antiproliferative agent-52 can be used for the research of ovarian cancer, non-small cell lung cancer .

HY-179430

TTK-IN-5	Mps1	Cancer
TTK-IN-5 is an orally active covalent threonine tyrosine kinase (TTK) inhibitor with selectivity (IC₅₀ = 8.918 nM). TTK-IN-5 exhibits anti-proliferative potencies against MDA-MB-231, A2780, HCT116, HCC1569 and MKN1 cell lines (IC₅₀ values of 0.113 μM, 0.476 μM, 3.136 μM, 3.649 μM, and 1.856 μM, respectively). TTK-IN-5 potently suppresses tumor growth without notable toxicity in A2780 and MDA-MB-231 xenograft mouse models. TTK-IN-5 can be used for the research of cancer such as breast cancer and ovarian cancer .

HY-N15168

3,4,5'-Trihydroxy-3'-methoxy-trans-stilbene	Parasite	Infection Cancer
3,4,5'-Trihydroxy-3'-methoxy-trans-stilbene (Compound 3) is a stilbenoid compound found in Stuhlmannia moavi. 3,4,5'-Trihydroxy-3'-methoxy-trans-stilbene exerts weak proliferative inhibitory activity and antimalarial activity with IC₅₀ values of 54 and 27 μM against A2780 human ovarian cancer cells and Plasmodium falciparum. 3,4,5'-Trihydroxy-3'-methoxy-trans-stilbene can be used for researches of ovarian cancer and malaria .

HY-119694

Rotenolone	Drug Metabolite Mitochondrial Metabolism Cytochrome P450	Cancer
Rotenolone is a metabolite of Rotenone (HY-B1756), inhibitor of Mitochondrial complex I, and antiproliferative agent, with an IC₅₀ of 137 nM against bovine complex I. Rotenolone undergoes biotransformation via multiple cytochrome P450 isoenzymes in rainbow trout liver microsomes. Rotenolone exhibits anticancer activity against ovarian cancer, breast cancer, prostate cancer, non-small cell lung cancer, and colon cancer. Rotenolone can be used in studies related to ovarian cancer, breast cancer, prostate cancer, non-small cell lung cancer, and colon cancer .

HY-10226R

JNJ-16241199 (Standard) R306465 (Standard)	Reference Standards Apoptosis HDAC	Cancer
JNJ-16241199 (Standard) is the analytical standard of JNJ-16241199 (HY-10226). This product is intended for research and analytical applications. JNJ-16241199 (R306465) is an orally active, selectivehydroxamate-based histone deacetylase (HDAC) inhibitor, with theIC₅₀of 3.3 nM and 23 nM for HDAC1and HDAC8, respectively.JNJ-16241199induces histone 3 acetylation and strongly increases the expression of p21waf1, cip1 in A2780 ovarian carcinoma cells.JNJ-16241199 inducescell apoptosisand shows anticancer activityin a broad spectrum of human malignancies. JNJ-16241199 can be used for cancer study .

HY-181658

Antimalarial agent 59	Parasite	Infection Cancer
Antimalarial agent 59 is an antimalarial agent. Antimalarial agent 59 inhibits the growth of Chloroquine (HY-17589A)-resistant FcB1 strain of Plasmodium falciparum with an IC₅₀ of 46 nM. Antimalarial agent 59 also shows cytotoxic activity against cancer cells. Antimalarial agent 59 can be used for the researches of malaria and ovarian cancer .

HY-156484

SPR519	PI3K mTOR	Cancer
SPR519 is a selective, orally active dual PI3Kα/mTOR kinase inhibitor, with an IC₅₀ of 0.03 μM against PI3Kα and an IC₅₀ of 0.01 μM against mTOR. SPR519 exhibits anticancer effects in ovarian cancer and colon cancer xenograft models. SPR519 can be used for the research of solid tumors (ovarian cancer, colon cancer) .

HY-182780

LSPN925	Drug Derivative	Cancer
LSPN925 is an anticancer agent. LSPN925 exhibits cytotoxic and antiproliferative activities against tumor cells. LSPN925 has predicted oral bioavailability, low risks of hepatotoxicity and acute toxicity, and no risk of cardiotoxicity. LSPN925 can be used for the research of ovarian cancer, melanoma and breast cancer .

HY-184155

LC1343	Thymidylate Synthase Apoptosis	Cancer
LC1343 is a human thymidylate synthase (hTS) inhibitor with an IC₅₀ of 7 μM. LC1343 inhibits cancer cell growth and induces apoptosis in cancer cells. LC1343 can be used for the research of ovarian cancer, colorectal cancer, and pancreatic cancer .

HY-N19113

Emindole SB	Endogenous Metabolite	Infection Cancer
Emindole SB is an anticancer agent. Emindole SB can be isolated from Penicillium species. Emindole SB exerts anticancer effects against ovarian cancer, breast cancer and lymphoma. Emindole SB shows no toxicity to Caenorhabditis elegans. Emindole SB can be used in studies related to ovarian cancer, lymphoma and breast cancer .

HY-138195

NEO212	DNA/RNA Synthesis Apoptosis FAK Src MMP Autophagy	Cancer
NEO212 is an orally active, blood-brain barrier permeable conjugate of Temozolomide (TMZ) (HY-17364) and Perillyl Alcohol (POH) (HY-N7000), with potent anticancer activity. NEO212 overcomes classical TMZ resistance and DNA alkylation by depleting MGMT. By inhibiting the FAK/Src signaling pathway, NEO212 reduces the production of MMP2 and MMP9, induces mesenchymal-epithelial transition, and inhibits the migration, invasion and tumor progression of glioma stem cells. NEO212 disrupts autophagy flux to enhance mitochondrial apoptosis; it induces differentiation of acute myeloid leukemia (AML) cells into macrophages and proliferation arrest .

HY-153514

HDAC-IN-54	HDAC Microtubule/Tubulin Apoptosis	Cancer
HDAC-IN-54 is a HDAC inhibitor with an IC₅₀ of 25 nM against human HDAC1, 66 nM against HDAC2, 6.5 nM against HDAC3, and 281 nM against HDAC6. HDAC-IN-54 induces acetylation of α-tubulin and histone H3. HDAC-IN-54 acts synergistically with cisplatin to induce cancer cell apoptosis. HDAC-IN-54 can be used in research related to head and neck cancer, ovarian cancer, and tongue squamous cell carcinoma .

Cat. No.	Product Name	Type